Docetaxel for hormone-naive prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden
Name:
mdz248.001.pdf
Size:
105.2Kb
Format:
PDF
Description:
From UNPAYWALL. Conference abstract
Authors
Clarke, Noel WAli, Adnan
Ingleby, FC
Hoyle, Alex P
Calvert, J
Attard, G
Chowdhury, S
Dearnaley, D
Douis, H
Gillessen, Silke
Jones, R
Malik, Z
Mason, MD
Millman, R
Parker, C
Rush, HL
Omlin, AG
Sydes, MR
Parmar, MKB
James, ND
Affiliation
The Departments of Surgery and Urology, The Christie and Salford Royal Hospitals, ManchesterIssue Date
2019
Metadata
Show full item recordCitation
Clarke NW, Ali A, Ingleby FC, Hoyle A, Calvert J, Attard G, et al. 844O Docetaxel for hormone-naïve prostate cancer: Results from long-term follow-up of metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476) and sub-group analysis by metastatic burden. Annals of Oncology. 2019;30(Supplement_5).Journal
Annals of OncologyDOI
10.1093/annonc/mdz248.001Additional Links
https://dx.doi.org/10.1093/annonc/mdz248.001Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdz248.001